Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD107 versus enoxaparin for venous thromboembolism prevention after elective primary unilateral total knee arthroplasty
CTR20261040Phase 2Active
- Sponsor
- Jingyin Biopharma
- Start
- Apr 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SRSD107 in venous thromboembolism (VTE) (2 arms), sponsored by Jingyin Biopharma. Primary endpoint: Incidence of total venous thromboembolism events. Started Apr 2026; status: active.
02
Drugs
SRSD107
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20261040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261040.